(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
09 October 2025 (09.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/212726 A3

(51) International Patent Classification:
C07K 16/22 (2006.01) *A01K 67/0276* (2024.01)
C07K 16/28 (2006.01) *C12N 5/10* (2006.01)
A61K 39/00 (2006.01)

(21) International Application Number:
PCT/US2025/022664

(22) International Filing Date:
02 April 2025 (02.04.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/574,664 04 April 2024 (04.04.2024) US

(71) Applicant: **COMPASS THERAPEUTICS, INC.** [US/US]; 80 Guest Street, Suite 601, Boston, Massachusetts 02135 (US).

(72) Inventors: **ALBU, Diana**; c/o Compass Therapeutics, Inc., 80 Guest Street, Suite 601, Boston, Massachusetts 02135 (US). **ULUMBEN, Amy Daniel**; c/o Compass Therapeutics, Inc., 80 Guest Street, Suite 601, Boston, Massachusetts 02135 (US). **VISINTIN, Alberto**; c/o Compass Therapeutics, Inc., 80 Guest Street, Suite 601, BOSTON, Massachusetts 02135 (US). **SACHSENMEIER, Kris**; c/o Compass Therapeutics, inc., 80 Guest Street, Suite 601, Boston, Massachusetts 02135 (US). **SCHUETZ, Thomas**; c/o Compass Therapeutics, Inc., 80 Guest Street, Suite 601, Boston, Massachusetts 02135 (US). **DUFFY, Rachel**; c/o Compass Therapeutics, Inc., 80 Guest Street, Suite 601, Boston, Massachusetts 02135 (US). **GONG, Bing**; c/o Compass Therapeutics, Inc., 80 Guest Street, Suite 601, Boston, Massachusetts 02135 (US).

(74) Agent: **LENTZ, Shannon** et al.; Brownstein Hyatt Farber Schreck, LLP, 675 15th Street, Suite 2900, Denver, Colorado 80202 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: COMBINATION OF ANTIBODIES TARGETING DLL4/VEGF AND CD137 AGONISTS OR ANTI-PD1/ANTI-PD-L1 ANTIBODIES FOR THE TREATMENT OF CANCER

(57) Abstract: The present disclosure relates to, *inter alia*, methods of combining antibodies and immunotherapy for treating, or ameliorating one or more symptoms of cancer.




Fig.2

[Continued on next page]

WO 2025/212726 A3

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) **Date of publication of the international search report:**
04 December 2025 (04.12.2025)